🔬 New at Pharmidex: In Vivo CAR-T Studies
February 12, 2026
Pharmidex now offers integrated in vivo CAR-T study support, combining robust in-life pharmacology with advanced flow cytometry–based cellular analysis.
We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner.
Let’s talk.
🌐 www.pharmidex.com

#Pharmidex #CART #CellTherapy #PreclinicalResearch #ImmunoOncology

We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: 📄 “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" 📄 “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.

We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. 🔗 Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub

Pharmidex is proud to be the Networking Sponsor at the Immuno-Oncology & Biomarker Summit in London. Over the next two days, the event provides an opportunity to discuss the latest advances in immuno-oncology, biomarker discovery, and precision medicine. If you’re attending, come and say hello to Ash Alavijeh to connect and explore opportunities to collaborate.




